Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.

Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T.

J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1284-93. Erratum in: J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):141.

PMID:
17023867
2.

A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.

Wigal SB, Greenhill LL, Nordbrock E, Connor DF, Kollins SH, Adjei A, Childress A, Stehli A, Kupper RJ.

J Child Adolesc Psychopharmacol. 2014 Dec;24(10):562-9. doi: 10.1089/cap.2014.0100.

3.

NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.

Wigal SB, Childress AC, Belden HW, Berry SA.

J Child Adolesc Psychopharmacol. 2013 Feb;23(1):3-10. doi: 10.1089/cap.2012.0073. Epub 2013 Jan 5.

4.

Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.

Silva RR, Muniz R, Pestreich L, Childress A, Brams M, Lopez FA, Wang J.

J Child Adolesc Psychopharmacol. 2006 Jun;16(3):239-51.

PMID:
16768632
5.

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.

Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.

CNS Drugs. 2008;22(8):693-704.

PMID:
18601306
6.

Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.

Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):121-31. doi: 10.1089/cap.2010.0047. Epub 2011 Apr 13.

7.

Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, Huang YS, Yeh CB, Chou MC, Lin DY, Hou PH, Wu YY, Liu HJ, Huang YF, Hwang KL, Chan CH, Pan CH, Chang HL, Huang CF, Hsu JW.

J Child Adolesc Psychopharmacol. 2012 Jun;22(3):215-25. doi: 10.1089/cap.2011.0006. Epub 2012 Apr 26.

8.

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Weiss M, Hechtman L, Turgay A, Jain U, Quinn D, Ahmed TS, Yates T, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.

J Child Adolesc Psychopharmacol. 2007 Oct;17(5):675-88.

PMID:
17979587
9.

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.

Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.

J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1406-14.

PMID:
15502600
10.

Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).

Vitiello B, Abikoff HB, Chuang SZ, Kollins SH, McCracken JT, Riddle MA, Swanson JM, Wigal T, McGough JJ, Ghuman JK, Wigal SB, Skrobala AM, Davies M, Posner K, Cunningham C, Greenhill LL.

J Child Adolesc Psychopharmacol. 2007 Oct;17(5):593-604.

PMID:
17979580
11.

Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.

Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, Lasser R, Renna J, Duncan D.

Adv Ther. 2013 May;30(5):472-86. doi: 10.1007/s12325-013-0027-2. Epub 2013 May 17.

12.

Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).

Ghuman JK, Riddle MA, Vitiello B, Greenhill LL, Chuang SZ, Wigal SB, Kollins SH, Abikoff HB, McCracken JT, Kastelic E, Scharko AM, McGough JJ, Murray DW, Evans L, Swanson JM, Wigal T, Posner K, Cunningham C, Davies M, Skrobala AM.

J Child Adolesc Psychopharmacol. 2007 Oct;17(5):563-80.

PMID:
17979578
14.
15.

A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.

Schulz E, Fleischhaker C, Hennighausen K, Heiser P, Oehler KU, Linder M, Haessler F, Huss M, Warnke A, Schmidt M, Schulte-Markworth M, Sieder C, Klatt J, Tracik F.

J Child Adolesc Psychopharmacol. 2010 Oct;20(5):377-85. doi: 10.1089/cap.2009.0106.

PMID:
20973708
16.

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.

Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R.

J Child Adolesc Psychopharmacol. 2008 Jun;18(3):248-56. doi: 10.1089/cap.2007.0015.

PMID:
18582179
17.

Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.

Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, Fischer R, Ammer R; Study Group..

World J Biol Psychiatry. 2012 Jan;13(1):48-59. doi: 10.3109/15622975.2010.540257. Epub 2010 Dec 14.

18.

Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

Silva RR, Muniz R, Pestreich L, Brams M, Mao AR, Childress A, Wang J.

J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):199-208. doi: 10.1097/chi.0b013e31815cd9a4.

PMID:
18176337
19.

Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.

Wigal SB, Gupta S, Heverin E, Starr HL.

J Child Adolesc Psychopharmacol. 2011 Jun;21(3):255-63. doi: 10.1089/cap.2010.0083.

PMID:
21663428
20.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529

Supplemental Content

Support Center